X
[{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$50.1 million","upfrontCash":"$29.5 million","newsHeadline":"Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Autifony Therapeutics
Filters
×
FILTER:
Company
Sponsor
Country
Therapeutic Area
Study Phase
Companies By Therapeutic Area
Details:
Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Lead Product(s):
AUT00206
Therapeutic Area: Otolaryngology (Ear, Nose, Throat)
Product Name: AUT00206
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Boehringer Ingelheim GmbH
Deal Size: $50.1 million
Upfront Cash: $29.5 million
Deal Type: Termination
August 26, 2020